Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 0.750% 5/1
-
Market price (% of par)
-
86.32%
-
Total 13F principal
-
$726,411,131
-
Principal change
-
+$720,284,131
-
Total reported market value
-
$626,631,807
-
Number of holders
-
49
-
Value change
-
+$621,342,068
-
Number of buys
-
48
Institutional Holders of LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 as of Q2 2019
As of 30 Jun 2019,
LIGAND PHARMACEUTICALS INC - NOTE 0.750% 5/1 was held by
49 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$726,411,131
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, CANYON CAPITAL ADVISORS LLC, ADVENT CAPITAL MANAGEMENT /DE/, CAMDEN ASSET MANAGEMENT L P /CA, STEELHEAD PARTNERS LLC, CITADEL ADVISORS LLC, WOLVERINE ASSET MANAGEMENT LLC, STATE STREET CORP, Polar Capital LLP, and Davidson Kempner Capital Management LP.
This page lists
49
institutional bondholders reporting positions
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.